PCRX
Pacira BioSciences, Inc. Common Stock
stockNASDAQ
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 25.01 | 2026-10-01 | +45.34% | -2.000 |
| 1M | 25.87 | 2026-09-08 | +40.51% | -0.592 |
| 3M | 25.52 | 2026-07-08 | +42.44% | 0.188 |
| 6M | 23.25 | 2026-04-08 | +56.34% | -0.024 |
| 1Y | 23.41 | 2025-10-08 | +55.28% | 0.294 |
| 2Y | 15.66 | 2024-10-08 | +132.12% | — |
| 5Y | 47.97 | 2021-10-08 | -24.22% | 0.538 |
Pacira BioSciences, Inc. Common Stock (NASDAQ:PCRX) stock price today is $36.35, and today's volume is 20,534,243. PCRX is up 44.246% today. The 30 day average volume is 549,282. PCRX market cap is $1.45B with 39.86M shares outstanding.